Skip to main content
. 2020 Jun 8;4(3):e401. doi: 10.1097/HS9.0000000000000401

Figure 3.

Figure 3

Progression free survival regarding best reponse to nivolumab monotherapy and alloHSCT consolidation. A. Progression-free survival (PFS) in patients with progression as best response achieved during nivolumab monotherapy vs other patients. B. Progression-free survival (PFS) in patients with nivolumab-bendamustine as bridge to allogeneic stem cell transplantations vs other patients.